WAT — Waters Corporation

Summary of Waters Corporation Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $1.645 billion, comprising $828 million in organic revenue (up 7% reported, 9% in constant currency) and $817 million from acquired Waters Biosciences and Diagnostic Solutions (4% growth).
• Adjusted EPS: $3.05, at the high end of guidance, reflecting a 3% increase year-over-year.
• Gross Margin: 54%, consistent with expectations; Operating Margin: 25%.
• Free Cash Flow: $202 million, after integration costs and severance payments.
• Geographic Revenue Breakdown: Americas: $690 million, Europe: $505 million, Asia: $450 million.

2. Strategic Updates and Business Highlights

• Acquisition Integration: Successful execution of a 180-day growth revitalization plan for acquired businesses, leading to improved performance and revenue synergies.
• Analytical Sciences Division: 7% growth driven by strong demand in pharma and academic sectors, with notable new product launches enhancing market position.
• Biosciences Division: Improved growth trajectory, particularly in Flow Clinical, which grew 8% due to enhanced commercial execution.
• Advanced Diagnostics Division: 7% growth, with significant contributions from the newly launched BACTEC FXI blood culture system, which is expected to drive future growth.
• Materials Science Division: Returned to high single-digit growth, driven by electronics and aerospace applications.

3. Forward Guidance and Outlook

• 2026 Guidance: Organic constant currency revenue growth revised to 7% to 9%, with total reported revenue expected between $6.415 billion and $6.476 billion.
• Adjusted EPS Guidance: Now projected at $14.45 to $14.65, reflecting year-over-year growth of 10% to 12%.
• Q3 2026 Expectations: Anticipated organic constant currency revenue growth of 8% to 10%, with total revenue forecasted at $1.745 billion to $1.762 billion.

4. Challenges and Points of Concern

• Foreign Exchange Impact: A stronger U.S. dollar is expected to negatively affect revenue by approximately 60 basis points.
• China Market Headwinds: Ongoing challenges in the Chinese market, particularly in the Diagnostics sector, though improvements are anticipated with localized product offerings.
• Instrument Replacement Cycle: Despite recent growth, the organic growth of instrument revenue remains below historical averages, indicating a prolonged recovery period.
• Competitive Pressures: Concerns about maintaining nimbleness in pricing strategies due to new approval processes for discounts in the acquired businesses.

5. Notable Q&A Insights

• BD Life Sciences Growth: Executives expressed confidence in achieving over 6% growth in the BD businesses by the end of 2026, driven by improved execution and product launches.
• Pricing Strategy: The company is on track to achieve a 150 basis point increase in pricing, with early successes noted in Q2.
• Reshoring Opportunities: Executives indicated that reshoring could provide incremental growth opportunities, particularly in the U.S. pharma sector, with significant capital expenditures underway.
• Flow Cytometry Initiatives: The launch of the FACSDiscover A7 is expected to drive growth in the Flow Research segment, with improved market conditions in the U.S. and China anticipated to bolster performance.
• Cost Actions: The company has successfully implemented cost-saving measures, with a run rate of $200 million expected to support margin expansion in the upcoming years.

Overall, Waters Corporation reported strong financial performance in Q2 2026, driven by effective integration of acquired businesses and robust growth in key divisions, while also navigating challenges in foreign exchange and specific markets like China. The outlook remains positive, with strategic initiatives in place to sustain growth momentum.